Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.
Number of participants with Adverse events will be covered in Adverse Events section.
Inclusion Criteria:
Exclusion Criteria:
Capital Federal, Ciudad Auton. de Buenos Aires 1425, Argentina
Hohehot, Inner Mongolia 010050, China
Sittard-Geleen, 6162 BG, Netherlands
City of San Fernando, 2000, Philippines
Incheon Gwangyeogsi,, Incheon Gwang''yeogsi 403-720, South Korea
NakhonRatchasima, 30000, Thailand
Kampus, 07058, Turkey (Türkiye)